Insmed (NASDAQ:INSM) PT Raised to $72.00 at JPMorgan Chase & Co.

Insmed (NASDAQ:INSMFree Report) had its price objective raised by JPMorgan Chase & Co. from $55.00 to $72.00 in a research note released on Thursday morning, Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

INSM has been the topic of several other research reports. Barclays boosted their target price on shares of Insmed from $40.00 to $63.00 and gave the stock an overweight rating in a report on Wednesday, May 29th. UBS Group boosted their target price on shares of Insmed from $46.00 to $58.00 and gave the stock a buy rating in a report on Wednesday, May 29th. TD Cowen boosted their price target on shares of Insmed from $45.00 to $67.00 and gave the stock a buy rating in a research report on Wednesday, May 29th. Stifel Nicolaus boosted their price target on shares of Insmed from $39.00 to $67.00 and gave the stock a buy rating in a research report on Friday, May 31st. Finally, Bank of America restated a buy rating and issued a $40.00 price target on shares of Insmed in a research report on Tuesday, May 28th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $62.38.

Get Our Latest Stock Analysis on Insmed

Insmed Price Performance

Shares of NASDAQ:INSM opened at $67.99 on Thursday. Insmed has a 1-year low of $19.68 and a 1-year high of $68.08. The company has a market capitalization of $10.10 billion, a P/E ratio of -13.00 and a beta of 1.12. The firm’s 50 day simple moving average is $38.28 and its two-hundred day simple moving average is $31.73.

Insmed (NASDAQ:INSMGet Free Report) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.06) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.16. The company had revenue of $75.50 million during the quarter, compared to analysts’ expectations of $77.76 million. During the same period last year, the firm posted ($1.17) EPS. Insmed’s quarterly revenue was up 15.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Insmed will post -4.5 earnings per share for the current fiscal year.

Insider Transactions at Insmed

In other news, insider Martina M.D. Flammer sold 21,195 shares of the company’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $55.00, for a total value of $1,165,725.00. Following the transaction, the insider now directly owns 106,134 shares in the company, valued at $5,837,370. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, insider Martina M.D. Flammer sold 21,195 shares of the company’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $55.00, for a total value of $1,165,725.00. Following the transaction, the insider now directly owns 106,134 shares in the company, valued at $5,837,370. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Sara Bonstein sold 220,564 shares of the company’s stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $50.00, for a total transaction of $11,028,200.00. Following the completion of the transaction, the chief financial officer now owns 117,481 shares in the company, valued at $5,874,050. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 295,842 shares of company stock worth $13,762,062. Insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. International Assets Investment Management LLC purchased a new stake in Insmed in the fourth quarter worth about $25,000. EntryPoint Capital LLC purchased a new stake in Insmed in the first quarter worth about $33,000. Fidelis Capital Partners LLC purchased a new stake in Insmed in the first quarter worth about $34,000. Headlands Technologies LLC purchased a new stake in Insmed in the first quarter worth about $59,000. Finally, Quarry LP purchased a new stake in Insmed in the fourth quarter worth about $116,000.

Insmed Company Profile

(Get Free Report)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Read More

Analyst Recommendations for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.